On January 13, 2022, Aadi Bioscience, Inc. (the "Company") entered into that certain Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the "Agreement") with Fresenius Kabi, LLC pursuant to which Fresenius Kabi will manufacture Fyarro (sirolimus protein-bound particles for injectable suspension) (albumin-bound), for intravenous use ("Fyarro") for the Company, and the Company will purchase Fyarro as a finished drug product from Fresenius Kabi, on a purchase-order basis. In addition to manufacturing, Fresenius Kabi will perform specified labeling, packaging and serialization activities in respect of Fyarro for the benefit of the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.12 USD | +4.95% | +21.14% | +4.95% |
Mar. 13 | Transcript : Aadi Bioscience, Inc., Q4 2023 Earnings Call, Mar 13, 2024 | |
Mar. 13 | Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.95% | 52.05M | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B | |
-4.33% | 8.5B |
- Stock Market
- Equities
- AADI Stock
- News Aadi Bioscience, Inc.
- Aadi Bioscience, Inc. Enters into Certain Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product with Fresenius Kabi, LLC